Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587713 | 0.88 | HTR2C (0.59) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I | |
| SCHEMBL29587401 | 0.82 | HCRTR2 (0.69) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I | |
| SCHEMBL29979939 | 0.81 | HTR2C (0.58) | HTR2CCACNA1GCACNA1HCACNA1ICPB1 | |
| SCHEMBL17234175 | 0.81 | HTR2C (0.58) | HTR2CCACNA1GCACNA1HCACNA1ICPB1 | |
| SCHEMBL30800900 | 0.80 | HCRTR2 (0.60) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I | |
| SCHEMBL29587569 | 0.80 | HCRTR2 (0.60) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I | |
| SCHEMBL22969736 | 0.79 | HCRTR2 (0.40) | HCRTR2HTR2CCPB1CYP2C9CYP2C19 | |
| SCHEMBL22321336 | 0.78 | HCRTR2 (0.49) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I | |
| SCHEMBL24589437 | 0.78 | KLK7 (0.53) | CYP2C19ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2389760 | 0.77 | HTR2C (0.64) | HCRTR2HTR2CCACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4010314-B1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4255429-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022119888-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | HCRTR2 1/4885HTR2C 25/4885CACNA1G 805/4885 |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HTR2C 34/4885CACNA1G 1659/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HTR2C 41/4885CACNA1G 1873/4885 |
| US-20230018413-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HTR2C 41/4885CACNA1G 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.